JPWO2023054292A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023054292A5
JPWO2023054292A5 JP2022565717A JP2022565717A JPWO2023054292A5 JP WO2023054292 A5 JPWO2023054292 A5 JP WO2023054292A5 JP 2022565717 A JP2022565717 A JP 2022565717A JP 2022565717 A JP2022565717 A JP 2022565717A JP WO2023054292 A5 JPWO2023054292 A5 JP WO2023054292A5
Authority
JP
Japan
Prior art keywords
cov
sars
pharmaceutical composition
composition according
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022565717A
Other languages
English (en)
Japanese (ja)
Other versions
JP7236065B1 (ja
JPWO2023054292A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/035803 external-priority patent/WO2023054292A1/ja
Application granted granted Critical
Publication of JP7236065B1 publication Critical patent/JP7236065B1/ja
Publication of JPWO2023054292A1 publication Critical patent/JPWO2023054292A1/ja
Publication of JPWO2023054292A5 publication Critical patent/JPWO2023054292A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022565717A 2021-09-28 2022-09-27 トリアジン誘導体を含有する医薬組成物 Active JP7236065B1 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP2021157929 2021-09-28
JP2021157929 2021-09-28
JP2021171725 2021-10-20
JP2021171725 2021-10-20
JP2022000723 2022-01-05
JP2022000723 2022-01-05
JP2022015035 2022-02-02
JP2022015035 2022-02-02
JP2022131590 2022-08-22
JP2022131590 2022-08-22
PCT/JP2022/035803 WO2023054292A1 (ja) 2021-09-28 2022-09-27 トリアジン誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP7236065B1 JP7236065B1 (ja) 2023-03-09
JPWO2023054292A1 JPWO2023054292A1 (https=) 2023-04-06
JPWO2023054292A5 true JPWO2023054292A5 (https=) 2023-09-06

Family

ID=85476839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565717A Active JP7236065B1 (ja) 2021-09-28 2022-09-27 トリアジン誘導体を含有する医薬組成物

Country Status (8)

Country Link
US (1) US20250127788A1 (https=)
EP (1) EP4410292A4 (https=)
JP (1) JP7236065B1 (https=)
KR (1) KR20240082359A (https=)
CN (1) CN119818502A (https=)
AU (1) AU2022353486A1 (https=)
CA (1) CA3233206A1 (https=)
MX (1) MX2024003600A (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2024193451A1 (en) * 2023-03-17 2024-09-26 Ascletis BioScience Co., Ltd Triazine derivatives, method of making and method of using thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036410A1 (en) * 1998-01-13 1999-07-22 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
TW201331188A (zh) 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4282420A4 (en) * 2021-01-20 2024-11-27 National University Corporation Hokkaido University ANTIVIRAL AGENT
EP4313097A4 (en) * 2021-03-29 2025-03-19 Shireen Nature Company for General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija

Similar Documents

Publication Publication Date Title
JPWO2023054292A5 (https=)
US11267801B2 (en) Therapeutic compounds
ES2670769T3 (es) Derivados de (hetero)arilacetamida como agentes antirretrovirales
JP2024516371A5 (https=)
JP2023166406A5 (https=)
JP2023002662A5 (https=)
CN113906013A (zh) 吡啶氮氧化合物及其制备方法和用途
JP2020507589A5 (https=)
JP2022505841A5 (https=)
JP2024541569A5 (https=)
JP2022505637A5 (https=)
JP2024544538A5 (https=)
JPWO2023054732A5 (https=)
JPWO2023095860A5 (https=)
JP2021522255A5 (https=)
JP2023549849A5 (https=)
JP5744003B2 (ja) 抗ウイルス化合物を調製する方法
JP2019536778A5 (https=)
JP2020533402A5 (https=)
JPWO2025005306A5 (https=)
MX2022011392A (es) Compuestos inhibidores de phd, composiciones y uso.
JP2023518390A5 (https=)
EP2506854B1 (en) Composition for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker
EP4248960A3 (en) Novel triterpene derivatives as hiv inhibitors
JP2022529845A5 (https=)